Keywords: Novartis, Ranibizumab, Lucentis, Diabetic macular edema, Vision loss

Novartis’ ranibizumab significantly more effective than standard of care in treating vision loss due to diabetes complication DME

Article | 24 May 2010

Print This

Swiss drug major Novartis says that the first results of the RESTORE Phase III study show that ranibizumab is significantly ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in